Tradestie Institutional Equity Comparison Engine

EQ vs CLYM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

EQ Overall Edge

EQ Captures Institutional Edge (2โ€“2 Pillars ยท 4โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Equillium, Inc. Common Stock (EQ) driven by superior Valuation, Options & Structure while CLYM counters with relative strength in Growth & Margin, Momentum & Technical. Fundamentally, EQ trades at 1.5x Forward P/E with 0.0% operating margin (-52.3% YoY revenue) versus CLYM at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, EQ sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner EQ
EQ 1.5x vs CLYM N/M Fwd P/E
Growth & Margin Winner CLYM
Op Margin 0.0% vs 0.0% ยท YoY -52.3% vs +0.0%
Momentum & Technical Winner CLYM
1Y +5.0% vs +399.5% ยท 52W Pos 9% vs 45%
Options & Structure Winner EQ
UNCLASSIFIED (100th %ile IV) vs UNCLASSIFIED (N/A IV)
EQ NASDAQ
Equillium, Inc. Common Stock
Pharmaceutical Preparations
$1.06
-5.36% 1D
Market Cap $92.2M
1M Return -16.54%
1Y Return +4.95%
Forward P/E 1.5x
Unified AI Score
48.6 / 100 HOLD
Tech 29.0 Fund 55.0 Flow 63.0 Mom 60.0
CLYM NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.19
-0.97% 1D
Market Cap $545.1M
1M Return -12.81%
1Y Return +399.46%
Forward P/E N/M
Unified AI Score
43.7 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 50.0 Mom 54.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: EQ +4.95% CLYM +399.46% Spread: +394.51 pp (CLYM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
EQ TTM Op. Margin: 0.0% CLYM TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EQ vs CLYM. Trailing 12-month operating profitability (EQ 0.0% vs CLYM 0.0%) and valuation multiples (EQ 1.5x vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: EQ (4) vs CLYM (4)
Institutional Metric EQ CLYM Criterion Row Winner
Market Capitalization Scale $92.2M $545.1M Larger Scale CLYM
Trailing P/E Ratio Valuation 1.5x N/M Lower Multiple EQ
Forward P/E Ratio Valuation 1.5x N/M Lower Multiple EQ
Revenue Growth (YoY) Growth -52.3% +0.0% Higher Growth CLYM
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -59.0% -29.3% Higher ROE CLYM
52-Week Range Position Momentum 9% ($1โ€“$4) 45% ($2โ€“$18) Stronger Trend CLYM
Beta / 30D Volatility Risk Regime 1.54ฮฒ ยท 89% Vol 1.42ฮฒ ยท 106% Vol Lower Realized Risk EQ
Unified Institutional Score Composite Signal 48.6 / 100 (HOLD) 43.7 / 100 (HOLD) Higher Composite EQ

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full EQ vs CLYM Buy Guide
EQ UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live EQ Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CLYM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CLYM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither EQ nor CLYM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.